A few days ago, a friend asked if I’d made any New Year’s resolutions. “No,” I replied, shrugging. Then I changed my mind and answered “yes.” Seeing her bewildered expression upon my contradictory response, I knew I had to explain. I used to enjoy the tradition of making resolutions every…
The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the…
Neurosense Therapeutics has entered a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS). The binding term sheet, a preliminary document outlining the terms and conditions of a potential agreement between the…
A Phase 1 clinical trial testing RAG-17, an investigational therapy for people with amyotrophic lateral sclerosis (ALS) carrying mutations in the SOD1 gene, has dosed its first participant. The trial (NCT06556394) aims to determine the safety and tolerability, pharmacological properties, and preliminary signs of efficacy of multiple dose levels of…
This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other present or future content posted by the contributor, not expressly designated as “Mitsubishi Tanabe Pharma America, Inc. – sponsored content” is not associated with MTPA. Eugene is an actual patient…
People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor neuron diseases (MNDs), but heart and metabolism problems are linked with faster disease progression and worse survival rates among people who already have MND. That’s according to the study, “…
I recently listened to a podcast called “The Art of Manliness.” The episode was titled “The Winter Mindset — How Norwegians Love the Winter (And You Can Too).” I could relate, because I live in a northern climate that receives over 200 inches of snow each year. Winters in Michigan’s…
A muscle mass biomarker called the creatinine-to-cystatin C ratio (CCR) may indicate the risk of developing amyotrophic lateral sclerosis (ALS), a study that relied on a large-scale database shows. A lower ratio was associated with higher ALS risk, particularly in the participants between the ages of 40 and 65.
I named my column “Living Well with ALS” for many reasons. The most important one was that each word in the title had a deep meaning for me. Six years ago, when Bionews, the parent company of this website, invited me to write a patient column for…
Throughout 2024, ALS News Today brought our readers daily coverage of the latest in scientific breakthroughs, treatment advances, and clinical trial updates related to amyotrophic lateral sclerosis (ALS). Here is a list of the top 10 most-read articles published in 2024, along with a brief description. We look…
Get regular updates to your inbox.
